Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
China's Brain-Computer Interface Market Size Estimated to Reach 6.14 Billion Yuan by 2028, Puni Testing Up Over 10%
(Source: Caixin)
Recently, the National Medical Products Administration approved the registration application for Bori Kang Medical Technology (Shanghai) Co., Ltd.'s innovative implantable brain-computer interface hand motor function compensation system, achieving the world’s first launch of a brain-computer interface medical device. This marks the entry of the world’s first invasive brain-computer interface medical device into clinical application.
On March 16, the concept of brain-computer interfaces was active. As of the time of publication, component stocks such as Sponi Testing (300887.SZ) rose over 10%, while EVE Energy (300014.SZ), Innovation Medical (002173.SZ), Lepu Medical (300003.SZ), BGI Genomics (688114.SH), and Sanbo Neuroscience (301293.SZ) also gained.
According to previous reports by CCTV News, recently, the National Medical Products Administration approved the registration application for Bori Kang Medical Technology (Shanghai) Co., Ltd.'s innovative implantable brain-computer interface hand motor function compensation system, marking the world’s first launch of a brain-computer interface medical device. This signifies that the world’s first invasive brain-computer interface medical device has entered the clinical application stage.
Additionally, nine departments including the Jiangsu Provincial Department of Industry and Information Technology issued a notice, proposing that by 2030, at least 20 brain-computer interface products will pass medical device registration and approval. They also aim to guide key medical institutions to open clinical scenarios to enterprises, universities, and research institutes, and to establish specialized brain-computer interface research wards to meet the needs of product development, data collection, and clinical trials.
According to Precedence Research, the global brain-computer interface market size is approximately $2.62 billion in 2024, expected to reach $2.94 billion in 2025, and potentially grow to $12.4 billion by 2034, with a compound annual growth rate of 17.35% over ten years. Huafu Securities reports that the market size of brain-computer interfaces in China will be 3.2 billion yuan in 2024, projected to reach 6.14 billion yuan by 2028.
Huajin Securities believes that 2024 marks the critical year for the commercialization of the brain-computer interface industry. Policy guidance, technological iteration, and clinical breakthroughs are resonating to promote rapid industry development. Non-invasive technologies, characterized by high safety, low cost, and ease of popularization, are quickly moving from laboratories to the market; invasive/semi-invasive technologies, with their high-precision signal collection advantages, are focusing on high-value medical applications.